ViroPharma Lied About Antibiotic Exclusivity, Investor Says

Law360, New York (May 18, 2012, 7:21 PM EDT) -- A shareholder on Wednesday filed a proposed class action against ViroPharma Inc. seeking damages for stock losses allegedly sustained after the company wrongly led investors to believe it had secured three years of market exclusivity for its signature gastrointestinal antibiotic.

In a suit filed in Pennsylvania federal court, the shareholder accuses the company of misleading investors with statements in December that its antibiotic brand, Vancocin, would qualify for three years of market exclusivity thanks to a new condition of use established for the drug by the...
To view the full article, register now.